1. Antibody-drug Conjugate/ADC Related Apoptosis
  2. Antibody-Drug Conjugates (ADCs) Apoptosis
  3. Naratuximab emtansine

Naratuximab emtansine  (Synonyms: IMGN529; Debio 1562)

Cat. No.: HY-132260
Data Sheet Handling Instructions Technical Support

Naratuximab emtansine (IMGN529) is a CD37-targeted ADC consisting of a humanized IgG1 mAb coupled to the microtubule disruptor DM1. Naratuximab emtansine has high affinity and specificity for CD37, allowing ADC internalization, processing and intracellular release of DM1. Due to its ability to disrupt microtubule assembly, DM1 can subsequently induce cell cycle arrest and apoptosis.

For research use only. We do not sell to patients.

Naratuximab emtansine Chemical Structure

Naratuximab emtansine Chemical Structure

CAS No. : 1607824-64-5

Size Price Stock
1 mg USD 490 Ask For Quote & Lead Time
5 mg USD 1235 Ask For Quote & Lead Time
10 mg USD 1980 Ask For Quote & Lead Time

* Please select Quantity before adding items.

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Naratuximab emtansine (IMGN529) is a CD37-targeted ADC consisting of a humanized IgG1 mAb coupled to the microtubule disruptor DM1. Naratuximab emtansine has high affinity and specificity for CD37, allowing ADC internalization, processing and intracellular release of DM1. Due to its ability to disrupt microtubule assembly, DM1 can subsequently induce cell cycle arrest and apoptosis[1].

In Vitro

Naratuximab emtansine (IMGN529) (0.125 nM, 24 h) treatment alone induces activation of cystein 3/7 in DLBCL cell lines and this effect is significantly enhanced in the presence of rituximab (2 nM), which further induces an increase in cleaved PARP levels[1].
Naratuximab emtansine (IMGN529) (0-3 ng/mL) shows dose-dependent antibody-dependent cell-mediated cytotoxicity (ADCC) activity against U-2932 and SU-DHL-4 cell lines[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Naratuximab emtansine (IMGN529) (10 mg/kg, a single bolus) monotherapy is inactive against U-2932 tumor and when combined with rituximab significantly enhances anti-tumor activity and no significant toxicity or weight loss is observed over the course of the study in female CB.17-SCID mice with U2932[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

CAS No.
SMILES

[Naratuximab emtansine]

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Naratuximab emtansine
Cat. No.:
HY-132260
Quantity:
MCE Japan Authorized Agent: